Evert Jan Van Limbergen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Evert Jan Van Limbergen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- An-Sofie Verrijssen
Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands
2 shared publications - Brigitte Reniers
Research group NuTeC, Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium
2 shared publications - Burak Yalvac
Faculty of Engineering Technology—Nuclear Technological Centre (NuTeC), Hasselt University, Hasselt, Belgium
2 shared publications - Dries Colson
Faculty of Engineering Technology—Nuclear Technological Centre (NuTeC), Hasselt University, Hasselt, Belgium
2 shared publications - Frank Verhaegen
Maastricht University Medical Centre
2 shared publications - Ludwig Jerome Dubois
The M-Lab, Department of Precision Medicine, GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands
2 shared publications
Latest Publications
- 17 April 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (8) , 085007
Assessing dosimetric uncertainties in Papillon+ contact x-ray brachytherapy for rectal cancer: impact of beam quality and tumour geometry
Objective. To investigate the evolution of beam quality in the Papillon+ contact x-ray therapy device and its dosimetric impact, a fast and straightforward beam quality index (QI) measurement method was proposed and validated. Additionally, the dosimetric consequences of tumour intrusion into the applicator tube were examined through Monte Carlo (MC) simulations and, for the first time, direct in-applicator dose measurements. Approach. QI measurements were performed every four weeks from mid-2022. Half-value layer (HVL) and depth-dose profile measurements in a plastic water low energy range phantom were conducted twice, with a two-year interval. Dose distributions for tumour intrusion scenarios (2.5–10 mm) were assessed using MC simulations and Gafchromic film measurements inside the applicator tube. Gross tumour volume (GTV) dose calculations (physical and EQD2) were performed for varying tumour thicknesses, intrusion depths, and diameters. Main results. All methods consistently demonstrated progressive beam hardening over time, with the HVL increasing from 0.77 mm Al to 0.93 mm Al. This spectral shift, attributed to x-ray tube ageing and radiation-induced material changes, was reversibly corrected after service replacement of the flattening filter, restoring the soft spectrum (HVL ≈ 0.69 mm Al). Tumour intrusion produced the strongest dosimetric effect, with surface dose increases up to 2.4-fold at 10 mm intrusion, exceeding MC predictions. GTV D90 decreased with tumour thickness but increased sharply with intrusion depth, whereas tumour diameter and surrounding medium had a negligible impact. Significance. This work highlights the importance of systematic beam quality follow-up in contact x-ray brachytherapy systems. Routine QI monitoring, together with well-defined beam-quality specifications and action limits, enables early detection of deviations, timely maintenance, and sustained compliance of the delivered beam quality in clinical practice. Tumour positioning relative to and protrusion into the applicator remains the dominant factor affecting dose distribution, underscoring the need for precise clinical setup and ongoing device characterisation to ensure clinical accuracy and patient safety.
- 17 April 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (8) , 085007
Assessing dosimetric uncertainties in Papillon+ contact x-ray brachytherapy for rectal cancer: impact of beam quality and tumour geometry
Objective. To investigate the evolution of beam quality in the Papillon+ contact x-ray therapy device and its dosimetric impact, a fast and straightforward beam quality index (QI) measurement method was proposed and validated. Additionally, the dosimetric consequences of tumour intrusion into the applicator tube were examined through Monte Carlo (MC) simulations and, for the first time, direct in-applicator dose measurements. Approach. QI measurements were performed every four weeks from mid-2022. Half-value layer (HVL) and depth-dose profile measurements in a plastic water low energy range phantom were conducted twice, with a two-year interval. Dose distributions for tumour intrusion scenarios (2.5–10 mm) were assessed using MC simulations and Gafchromic film measurements inside the applicator tube. Gross tumour volume (GTV) dose calculations (physical and EQD2) were performed for varying tumour thicknesses, intrusion depths, and diameters. Main results. All methods consistently demonstrated progressive beam hardening over time, with the HVL increasing from 0.77 mm Al to 0.93 mm Al. This spectral shift, attributed to x-ray tube ageing and radiation-induced material changes, was reversibly corrected after service replacement of the flattening filter, restoring the soft spectrum (HVL ≈ 0.69 mm Al). Tumour intrusion produced the strongest dosimetric effect, with surface dose increases up to 2.4-fold at 10 mm intrusion, exceeding MC predictions. GTV D90 decreased with tumour thickness but increased sharply with intrusion depth, whereas tumour diameter and surrounding medium had a negligible impact. Significance. This work highlights the importance of systematic beam quality follow-up in contact x-ray brachytherapy systems. Routine QI monitoring, together with well-defined beam-quality specifications and action limits, enables early detection of deviations, timely maintenance, and sustained compliance of the delivered beam quality in clinical practice. Tumour positioning relative to and protrusion into the applicator remains the dominant factor affecting dose distribution, underscoring the need for precise clinical setup and ongoing device characterisation to ensure clinical accuracy and patient safety.
- 4 July 2024
- Published by Elsevier in Brachytherapy
- Vol. 23 (5) , 535-548
Dosimetry and Monte Carlo modelling of the Papillon+ contact X-ray brachytherapy device
- 4 July 2024
- Published by Elsevier in Brachytherapy
- Vol. 23 (5) , 535-548
Dosimetry and Monte Carlo modelling of the Papillon+ contact X-ray brachytherapy device
- Open Access
- 1 April 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 109 (5) , 1421-1430
Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study
- 1 April 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 109 (5) , 1421-1430
Open AccessToxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study
- Open Access
- 1 March 2021
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 27, 121-125
Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients?
- 1 March 2021
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 27, 121-125
Open AccessIs prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients?
- Open Access
- 9 May 2020
- Published by Wiley in Molecular Oncology
- Vol. 14 (7) , 1555-1568
Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED‐B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED‐B and has shown therapeutic potential when combined with cytokines, such as IL‐2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED‐B targeting for the imaging and treatment of various types of cancer. ED‐B‐centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody‐based targeted therapies.
- 9 May 2020
- Published by Wiley in Molecular Oncology
- Vol. 14 (7) , 1555-1568
Open AccessHuman fibronectin extra domain B as a biomarker for targeted therapy in cancer
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED‐B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED‐B and has shown therapeutic potential when combined with cytokines, such as IL‐2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED‐B targeting for the imaging and treatment of various types of cancer. ED‐B‐centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody‐based targeted therapies.